Forte Biosciences IncNASDAQ:FBRXNASDAQ FSI:D. Deficient (Issuer failed to meet continued listing requirements)
- LAST PRICE0.5710
- TODAY'S CHANGE (%)0.0000 (0.0000%)
- Bid / Lots0.5600/ 1
- Ask / Lots0.6400/ 1
- Open / Previous Close0.0000 / 0.5710
- Day Range---
- 52 Week Range
- Volume---
Search Criteria
Filter search criteria using below inputs
Click on magnifying glass icon to search
| Company | Country | Symbol |
|---|
- TSX Comp
- TSX Venture
- DJIA
- S&P 500
- NASDAQ
| Time | Volume | FBRX |
|---|---|---|
| 10:26 ET | 100 | 0.57 |
| 10:50 ET | 100 | 0.583 |
| 10:51 ET | 200 | 0.583 |
| 10:53 ET | 100 | 0.576 |
| 10:55 ET | 100 | 0.575 |
| 10:57 ET | 442 | 0.57 |
| 11:00 ET | 100 | 0.57 |
| 11:02 ET | 100 | 0.57 |
| 11:04 ET | 100 | 0.57 |
| 11:06 ET | 200 | 0.57 |
| 11:08 ET | 100 | 0.57 |
| 11:09 ET | 100 | 0.57 |
| 11:27 ET | 200 | 0.57 |
| 12:34 ET | 200 | 0.58 |
| 01:44 ET | 300 | 0.6 |
| 02:02 ET | 2000 | 0.55 |
| 02:11 ET | 200 | 0.5775 |
| 02:13 ET | 200 | 0.5775 |
| 02:15 ET | 200 | 0.5775 |
| 02:18 ET | 200 | 0.5775 |
| 02:20 ET | 300 | 0.5775 |
| 02:22 ET | 200 | 0.5775 |
| 02:24 ET | 200 | 0.5775 |
| 02:26 ET | 200 | 0.5775 |
| 02:27 ET | 300 | 0.5775 |
| 02:29 ET | 200 | 0.5775 |
| 02:31 ET | 200 | 0.5775 |
| 02:33 ET | 300 | 0.5775 |
| 02:36 ET | 200 | 0.5775 |
| 02:38 ET | 200 | 0.5775 |
| 02:40 ET | 300 | 0.5775 |
| 02:42 ET | 200 | 0.5775 |
| 02:44 ET | 200 | 0.5775 |
| 02:45 ET | 300 | 0.5775 |
| 02:47 ET | 8297 | 0.578764 |
| 02:49 ET | 4670 | 0.55 |
| 03:56 ET | 297 | 0.571 |
May 30, 2024
DJ Forte Biosciences Initiated at Buy by Brookline Capital, from 6:06AM ET on Thursday May 30, 2024 by Dow Jones
6:06AM ET on Thursday May 30, 2024 by Dow Jones
May 17, 2024
Forte Biosciences, Inc. Reports Inducement Grants Under Nasdaq Listing Rules, from 4:05PM ET on Friday May 17, 2024 by Dow Jones
4:05PM ET on Friday May 17, 2024 by Dow Jones
May 13, 2024
Forte Biosciences, Inc. Announces First Quarter 2024 Results and Provides Business Update, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones*DJ Forte Biosciences 1Q Loss/Shr 16c >FBRX, from 4:05PM ET on Monday May 13, 2024 by Dow Jones
4:05PM ET on Monday May 13, 2024 by Dow Jones
| Company sortable | Market Cap sortable | P/E Ratio (TTM) sortable | EPS Growth (5yr) sortable |
|---|---|---|---|
Forte Biosciences Inc | 21.6M | -0.6x | --- |
Eom Pharmaceutical Holdings Inc | 22.5M | -4.6x | --- |
Purple Biotech Ltd | 20.5M | -0.8x | --- |
Bioxytran Inc | 20.5M | -4.1x | --- |
Cocrystal Pharma Inc | 22.9M | -1.4x | --- |
Biora Therapeutics Inc | 23.0M | -0.1x | --- |
Company Information
Forte Biosciences, Inc. is a clinical-stage biopharmaceutical company focused on autoimmune and autoimmune-related diseases. The Company is advancing its product candidate, FB-102, which is a proprietary molecule with potentially broad autoimmune applications, including in such indications as graft-versus-host disease (GvHD), vitiligo, and alopecia areata (AA). The Company’s FB-102 program focuses on addressing key pathways implicated in these indications with a CD122 antagonist. CD122 is a subunit of IL-2/IL-15 receptors which are key regulators of NK cells and T cell subsets. It owns one United States patent for administering a combination of Gram-positive and Gram-negative bacteria along with metabolites for treatment of a wide variety of skin conditions. The Company’s subsidiaries include Forte Subsidiary, Inc., Forte Biosciences Emerald Limited, and Forte Biosciences Australia Pty Ltd.
Contact Information
- Headquarters
- 3060 PEGASUS PARK DRIVE, BUILDING 6DALLAS, TX, United States 75247
- Phone
- 310-618-6994
- Fax
- 302-655-5049
Executives
- Chairman of the Board, Chief Executive Officer
- Paul Wagner
- President, Chief Scientific Officer
- Hubert Chen
- Chief Financial Officer
- Antony Riley
- Independent Director
- Scott Brun
- Independent Director
- Stephen Doberstein
Our Ratings feature offers company-specific research ratings from providers such as First Call, S&P and Argus.
Open a New Account, or Login if you're a client.
You have access to a comprehensive selection of independent research reports from providers such as TD Securities, S&P, INK, and Argus.
Open a New Account, or Login if you're a client.
Market Cap | $21.6M |
|---|---|
Revenue (TTM) | $0.00 |
Shares Outstanding | 36.4M |
Dividend Yield | 0.00% |
Annual Dividend Rate | --- |
Ex-Dividend Date | 01-01-01 |
Pay Date | 01-01-01 |
Beta | 0.22 |
EPS | $-1.03 |
Book Value | $0.97 |
P/E Ratio | -0.6x |
Price/Sales (TTM) | --- |
Price/Cash Flow (TTM) | --- |
Operating Margin | --- |
Our Calendar feature allows you to view a wide selection of market and company events, including earnings, dividends, splits, rating changes, guidance, and more. Access past, current and future events in WebBroker.
Open a New Account, or Login if you're a client.
